1 min read
AbbVie Agrees to Pay Up to $2.54 Billion in DISCO Pharmaceuticals Collaboration
The companies will collaborate on developing novel cancer treatments, expanding AbbVie’s work in next-generation therapies.

AbbVie agreed to pay up to $2.54 billion to collaborate with Germany-based DISCO Pharmaceuticals on developing novel cancer treatments, expanding the drugmaker’s work in next-generation therapies.
The collaboration concerns novel cancer treatments.